The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects

• Published in: Clinical pharmacology and therapeutics Vol. 91; no. 2; p. 250
• Main Authors: Salazar, D E, Song, S H, Shi, J, Rohatagi, S, Heyrman, R, Wada, D R, Carrothers, T J
• Format: Journal Article
• Language: English
• Published: United States 01.02.2012
• Subjects: Adolescent; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - therapeutic use; Blood Pressure - drug effects; Child; Child, Preschool; Clinical Trials, Phase I as Topic - statistics & numerical data; Clinical Trials, Phase III as Topic - statistics & numerical data; Computer Simulation - statistics & numerical data; Dose-Response Relationship, Drug; Humans; Hypertension - drug therapy; Imidazoles - administration & dosage; Imidazoles - pharmacokinetics; Imidazoles - therapeutic use; Infant; Models, Statistical; Olmesartan Medoxomil; Tetrazoles - administration & dosage; Tetrazoles - pharmacokinetics; Tetrazoles - therapeutic use
• ISSN: 1532-6535
• DOI: 10.1038/clpt.2011.220

Modeling and simulation were used extensively in the development of an indication for the use of olmesartan medoxomil in pediatric patients with hypertension. Simulations based on models developed in adult patients indicated that two dose groups were sufficient to estimate a dose-response relationship, thereby reducing by one-third the number of subjects required for the phase III pediatric study. Model-based predictions for blood pressure reduction agreed with the observed results of the subsequent phase III study, showing statistically significant dose-response relationships with respect to both systolic and diastolic blood pressure. Previously established pharmacokinetic and exposure-response relationships in adults, adjusted for the influence of body weight on clearance (wt(0.80)), were confirmed in the pediatric population. Together, these findings support an olmesartan dosing recommendation in pediatric subjects aged 6 to 16 years of 10 mg for subjects weighing <35 kg and 20 mg for those weighing ≥35 kg.